Welcome to our dedicated page for Guardant Health news (Ticker: GH), a resource for investors and traders seeking the latest updates and insights on Guardant Health stock.
Guardant Health, Inc. develops precision oncology diagnostics and data products centered on blood and tissue testing for cancer care. Company news commonly covers the Guardant360 liquid biopsy and Guardant360 Tissue franchises, Guardant Reveal for molecular residual disease monitoring, Shield colorectal cancer screening, and InfinityAI real-world data and analytics.
Recurring updates include financial results across Oncology, Screening, and Biopharma & Data revenue categories; FDA companion diagnostic approvals for Guardant360 CDx; research presentations in tumor typing, therapy selection, methylation and multiomic testing; and biopharma collaborations that use Guardant tissue and liquid biopsy assays to support targeted therapy development.
Guardant Health (Nasdaq: GH) reported that its Board Compensation Committee approved inducement grants of restricted stock units (RSUs) for 149 new non-executive employees under its 2023 Employment Inducement Incentive Award Plan. The awards cover 46,044 shares of common stock with a grant date of August 3, 2026.
According to Guardant Health, the RSUs are granted under Nasdaq Listing Rule 5635(c)(4) as a material inducement to employment. One-third of each award vests annually on the anniversary of the vesting commencement date, subject to continued employment and the terms of the Inducement Plan and RSU agreements.
Guardant Health (Nasdaq: GH) reported second quarter 2026 revenue of $335.0 million, up 44% year over year, led by Oncology revenue of $219.1 million (+38%) on ~104,000 tests (+63%) and Screening revenue of $52.9 million, up over 250% on ~66,000 Shield tests. Biopharma & Data revenue rose 9% to $60.9 million. GAAP gross margin was 65%, with non-GAAP gross margin of 67%. The company posted a GAAP net loss of $120.1 million ($0.90 per share) and non-GAAP net loss of $56.2 million ($0.42 per share).
According to Guardant Health, 2026 revenue guidance increased to $1.34–$1.36 billion (36%–38% growth), with higher expectations for Oncology, Screening (Shield revenue of $218–$230 million, 270,000–285,000 tests) and low double-digit Biopharma & Data growth. The company highlighted multiple FDA approvals, inclusion of Shield in American Cancer Society screening guidelines, UnitedHealth Group coverage, and cash, cash equivalents and restricted cash of $1.2 billion at June 30, 2026.
Guardant Health (Nasdaq: GH) will participate in two upcoming investor conferences: the Canaccord Genuity 46th Annual Growth Conference in Boston, with a fireside chat on Wednesday, August 12 at 3:00 p.m. ET, and the Morgan Stanley 24th Annual Global Healthcare Conference in New York, with a fireside chat on Tuesday, September 15 at 7:45 a.m. ET. Interested parties can access live and archived webcasts via the Investors section of the Guardant Health website.
Guardant Health (Nasdaq: GH) announced a new tribute video featuring actor and cancer advocate Patrick Dempsey, honoring Americans who have died from colorectal cancer (CRC) and urging adults 45+ at average risk to get screened. The video highlights Guardant’s Shield blood test, described as an FDA-approved, non-invasive CRC screening option and the only blood test included in both American Cancer Society and National Comprehensive Cancer Network guidelines. According to Guardant Health, real-world experience in about 200,000 patients shows Shield has over 90% test completion, suggesting higher adherence than other screening methods. Shield is intended for average-risk individuals 45 or older and a positive result should be followed by colonoscopy.
Guardant Health (Nasdaq: GH) announced it will report second quarter 2026 financial results after market close on Thursday, July 30, 2026. Management will host a webcast conference call at 1:30 p.m. PT / 4:30 p.m. ET, accessible via the company’s investor relations website, with a replay available.
Guardant Health (Nasdaq: GH) announced that UnitedHealth Group now covers its FDA-approved Shield blood test for primary colorectal cancer screening in average-risk adults aged 45 and older. This policy makes United the first major U.S. commercial insurer to cover Shield for this population.
Approximately 40 million Americans are enrolled in UnitedHealth plans, contributing to over 100 million total covered lives with access to Shield. The test requires only a routine blood draw and is the first and only FDA-approved blood test included in both ACS and NCCN colorectal cancer screening guidelines.
Guardant Health (Nasdaq: GH) received FDA approval of its blood-based Guardant360 CDx test as a companion diagnostic for Boehringer Ingelheim’s HERNEXEOS (zongertinib) in adults with HER2 (ERBB2)-mutant advanced non-small cell lung cancer (NSCLC).
This is the 27th CDx indication for Guardant360 CDx globally and is supported by broad Medicare and commercial payer coverage representing over 300 million covered lives.
Guardant Health (Nasdaq: GH) and collaborators will present 38 abstracts, including an oral presentation with Pfizer, at the 2026 ASCO Annual Meeting. The data highlight liquid biopsy tests powered by InfinityAI, including Guardant360 Liquid CDx and the Shield blood test.
Key presentations cover pan-cancer companion diagnostics, enhanced ALK fusion detection in NSCLC, colorectal cancer screening, tissue-free MRD, and methylation-based tumor classification and tumor-of-origin prediction.
Guardant Health (Nasdaq: GH) announced that its FDA-approved Shield blood test is now recommended in updated American Cancer Society colorectal cancer screening guidelines. Shield is offered to average-risk adults 45+ who decline or have not completed stool-based or visual exams, aiming to improve screening participation.
Guardant Health (Nasdaq: GH) received FDA approval for Guardant360 Liquid CDx, described as the largest FDA-approved liquid biopsy panel. The test integrates genomic and epigenomic insights, offers a 100x wider genomic footprint than the prior Guardant360 CDx, and delivers results in as little as seven days.
According to Guardant Health, the approval transfers seven existing companion diagnostic indications, increases ctDNA detection sensitivity several-fold, and runs on its AI-enabled Smart Platform, supporting a unified liquid and tissue testing experience for advanced cancer care.